RELATED CONTENT
NEWS
- European generics firms, squeezed between innovators and payers, seek diversity
- 2011 US submission for Genentech/Curis' vismodegib in basal cell carcinoma
- Big pharma abandoning HIV discounts in middle-income countries, MSF claims
- English NHS must fund value based pricing system drugs

